BRPI0409321A - antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo - Google Patents
antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeoInfo
- Publication number
- BRPI0409321A BRPI0409321A BRPI0409321-6A BRPI0409321A BRPI0409321A BR PI0409321 A BRPI0409321 A BR PI0409321A BR PI0409321 A BRPI0409321 A BR PI0409321A BR PI0409321 A BRPI0409321 A BR PI0409321A
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- hybrid
- inducing
- immune response
- infectious
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"ANTìGENO HìBRIDO, COMPOSIçãO E MéTODO PARA INDUZIR UMA RESPOSTA IMUNE PARA UM AGENTE INFECCIOSO OU ANTìGENO DE TUMOR, MéTODO PARA TRATAR UMA DOENçA INFECCIOSA OU CáNCER, E, PEPTìDEO". Antígenos híbridos compreendendo pelo menos um domínio antigênico, pelo menos um domínio de ligação de proteína de choque térmico, e pelo menos um ligador de peptídeo melhorado no meio são descritos que são utilizáveis para a indução de uma resposta imune ao domínio antigênico quando administrados sozinhos ou em um complexo com pelo menos uma proteína de choque térmico. Os antígenos híbridos e complexos podem ser usados para tratar doenças infecciosas e cânceres que expressam um antígeno do domínio antigênico.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46246903P | 2003-04-11 | 2003-04-11 | |
US46374603P | 2003-04-18 | 2003-04-18 | |
US50341703P | 2003-09-16 | 2003-09-16 | |
US10/776,521 US7420037B2 (en) | 2003-02-13 | 2004-02-12 | Heat shock protein-based vaccines and immunotherapies |
PCT/US2004/004340 WO2004071457A2 (en) | 2003-02-13 | 2004-02-13 | Improved heat shock protein-based vaccines and immunotherapies |
US10/820,067 US7309491B2 (en) | 2003-04-11 | 2004-04-08 | Heat shock protein-based vaccines and immunotherapies |
PCT/US2004/010983 WO2004091493A2 (en) | 2003-04-11 | 2004-04-09 | Improved heat shock protein-based vaccines and immunotherapies |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0409321A true BRPI0409321A (pt) | 2006-05-23 |
Family
ID=35539709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0409321-6A BRPI0409321A (pt) | 2003-04-11 | 2004-04-09 | antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1617804A4 (pt) |
JP (1) | JP2007525448A (pt) |
KR (1) | KR20050121721A (pt) |
AU (1) | AU2004229458B2 (pt) |
BR (1) | BRPI0409321A (pt) |
CA (1) | CA2521809A1 (pt) |
MX (1) | MXPA05010881A (pt) |
WO (1) | WO2004091493A2 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007505147A (ja) * | 2003-09-12 | 2007-03-08 | アンティジェニクス インコーポレーテッド | 単純ヘルペスウイルス感染の治療および予防用ワクチン |
CA2605321A1 (en) | 2005-04-19 | 2006-10-26 | Eli Lilly And Company | Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease |
CY1112212T1 (el) * | 2008-04-24 | 2015-12-09 | Immatics Biotechnologies Gmbh | Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια |
PL2113253T3 (pl) * | 2008-04-30 | 2010-09-30 | Immatics Biotechnologies Gmbh | Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce |
CN103687616A (zh) * | 2011-07-21 | 2014-03-26 | 生物技术工具公司 | Dnak制剂 |
US10568948B2 (en) * | 2015-05-13 | 2020-02-25 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
MA52363A (fr) | 2018-04-26 | 2021-03-03 | Agenus Inc | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
US6663868B1 (en) * | 1995-08-18 | 2003-12-16 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
IL135860A0 (en) * | 1997-10-31 | 2001-05-20 | Sloan Kettering Inst Cancer | Conjugate heat shock protein-binding peptides |
AU2001257086B2 (en) * | 2000-04-17 | 2006-11-23 | Mee Hoe | Javelinization of protein antigens to heat shock proteins |
US20040071656A1 (en) * | 2001-12-26 | 2004-04-15 | Felix Wieland | Modulation of heat-shock-protein-based immunotherapies |
US7420037B2 (en) * | 2003-02-13 | 2008-09-02 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
-
2004
- 2004-04-09 CA CA002521809A patent/CA2521809A1/en not_active Abandoned
- 2004-04-09 AU AU2004229458A patent/AU2004229458B2/en not_active Expired - Fee Related
- 2004-04-09 KR KR1020057019351A patent/KR20050121721A/ko not_active Application Discontinuation
- 2004-04-09 BR BRPI0409321-6A patent/BRPI0409321A/pt not_active IP Right Cessation
- 2004-04-09 EP EP04759338A patent/EP1617804A4/en not_active Withdrawn
- 2004-04-09 JP JP2006509858A patent/JP2007525448A/ja active Pending
- 2004-04-09 WO PCT/US2004/010983 patent/WO2004091493A2/en active Application Filing
- 2004-04-09 MX MXPA05010881A patent/MXPA05010881A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20050121721A (ko) | 2005-12-27 |
MXPA05010881A (es) | 2006-05-31 |
EP1617804A4 (en) | 2007-07-25 |
WO2004091493A3 (en) | 2006-04-20 |
CA2521809A1 (en) | 2004-10-28 |
EP1617804A2 (en) | 2006-01-25 |
AU2004229458B2 (en) | 2009-11-19 |
WO2004091493A2 (en) | 2004-10-28 |
AU2004229458A1 (en) | 2004-10-28 |
JP2007525448A (ja) | 2007-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
BR0207283A (pt) | Anticorpos anti-egfr modificados com imunogenicidade reduzida | |
IL192679A0 (en) | Aglyco products and uses thereof | |
BR0113491A (pt) | Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente. | |
ATE474048T1 (de) | Her2/neu fusionsproteine | |
AR031250A1 (es) | Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon | |
ES2154738T3 (es) | Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora. | |
BR0316758A (pt) | Vacinas baseadas em levedura como imunoterapia | |
PT1157041E (pt) | Anticorpos para terapia e diagnostico de cancro | |
DE69030172T2 (de) | Impfstoffe gegen Krebs und Infektionskrankheiten | |
BR9712971A (pt) | Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica | |
AR045056A1 (es) | Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf | |
BR0207067A (pt) | Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo | |
PL343245A1 (en) | Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses | |
BR9612619A (pt) | Método e composição para reconformar antígenos multiepitópicos para iniciar uma resposta imunológica | |
HUP0302681A2 (hu) | Protein antigének hősokk fehérjékhez való gerelyszerű hozzákötése | |
WO2000025722A3 (en) | ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS | |
BRPI0409321A (pt) | antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo | |
MX2020001287A (es) | Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos. | |
BR0207528A (pt) | Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo | |
MY141459A (en) | Recombinant anti-idiotypic antibodies | |
UY26266A1 (es) | Antigeno asociado con tumores (r11) ley 17164 | |
BR0015597A (pt) | Uso de anticorpos como vacinas | |
HUP0302566A2 (hu) | Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására | |
WO2000073432A3 (en) | Activation of dendritic cells to enhance immunity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUI DADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |